Skip to main content
OpenTrials
Completed

NCT Number: NCT02429908

Post-Market Surveillance Study of the TM Ardis Interbody Fusion System

This study is a post-market clinical follow-up study to fulfill the post-market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2_Rev2_January 2012. The data collected from this study will serve the purpose of confirming safety and performance of the TM Ardis implant. The goal of this study is to demonstrate that implant is effective in reducing patient disability.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

OLV Ziekenhuis Department Neurosurgery, Aalst, Belgium

Loading trial locations.

About this study

This study is a post-market clinical follow-up (PMCF) study to fulfill the post-market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2_Rev2_January 2012. The data collected from this study will serve the purpose of confirming safety and performance of the TM Ardis implant. The goal of this study is to demonstrate that implant is effective in reducing patient disability, which will be assessed with the ODI questionnaire.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > or = 18 years
  • Degenerative disc disease DDD with up to Grade 1 spondylolisthesis or retrolis-thesis at the involved level. DDD is defined as discogenic back pain with degener-ation of the disc confirmed by history and radiographic studies.
  • ODI 40 out of 100
  • Back pain 4 out of 10
  • Mono segmental or two level lumbosacral disease
  • Skeletally mature patients
  • Six months failed conservative treatment.
  • Gave written consent to take part in the study by signing the Ethics Committee's approved Patient Informed Consent Form.
  • Physically and mentally able to comply with the protocol, including ability to read and complete required forms and adhere to the follow-up requirements of the pro-tocol.

Exclusion criteria

  • Prior surgical procedure at the index level(s) using the desired operative approach.
  • Severe degenerative lesions at more than two level of the lumbosacral spine.
  • Morbid obesity (BMI greater than or equal to 40).
  • Active local infection in or near the operative region.
  • Active systemic infection and/or disease.
  • Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation.
  • Known or suspected sensitivity to the implant materials.
  • Endocrine or metabolic disorders known to affect osteogenesis (e.g.Paget's disease, renal osteodystrophy, hypothyroidism)
  • Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs.
  • Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
  • Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care.
  • Pregnant.
  • Unwilling to follow postoperative instructions, in particular with respect to athletic or occupational activities.
  • Current vertebral metastatic tumors.
  • Symptomatic cardiac disease.
  • Severe congenital or acquired vertebral deformities.

Treatment and study plan

TM-Ardis Interbody

Device

The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).

Other names: Interbody Cage

Primary outcomes

  1. Improvement in ODI score

    Time frame: 24 months

    mean change in score of the ODI from baseline to 24 months post surgery. A 15 point improvement in ODI score will be considered as a success.

Secondary outcomes

  1. Safety - Adverse Events

    Time frame: 24 months

    All adverse events will be assessed by incidence and time to resolution of postoperative device-related complications and serious adverse events/ incidence and time to re-operation/ incidence and time to re-vision

  2. Fusion rate - X-ray

    Time frame: 3, 6, 12 and 24 month

    will be assessed at 3, 6, 12 and 24 months with the following fusion criteria: No evidence of radiolucency surrounding more than 50% of device, translational motion <3 mm and angular motion <5°.

  3. Patient Outcomes - Mean EQ-5D

    Time frame: 24 months

  4. Modic changes - MRI

    Time frame: 12 and 24 months

    Modic changes will be assessed by MRI

  5. Numerical Rating Scale (NRS) for back and leg

    Time frame: 3 , 6, 12, and 24 months

    Patients will grade back and leg pain with a numeric scale 0 - 10

  6. Zung self-rating depression scale score

    Time frame: 3, 6, 12, & 24 months

    Patients will complete a questionaire to assess depression.

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Registry information

Official study title

A Prospective, Multi-Center, Post-Market Surveillance Study to Assess the Clinical Efficacy and Fusion Rates of the Zimmer TM Ardis Interbody Fusion System

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Apr 29, 2015
Registry last updated
Mar 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.